Drug Trial Radar · NCT05675410
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,875
Planned (sponsor's estimate)
Start
May 11, 2023
Primary completion
Apr 28, 2031
Study completion Apr 28, 2031
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Bleomycin SulfateBiological
Given IV
Brentuximab VedotinDrug
Given IV
Computed TomographyProcedure
Undergo CT and/or PET-CT
CyclophosphamideDrug
Given IV
DacarbazineDrug
Given IV
Doxorubicin HydrochlorideDrug
Given IV
EtoposideDrug
Given IV
Etoposide PhosphateDrug
Given IV
Fludeoxyglucose F-18Other
Undergo FDG-PET
Involved-site Radiation TherapyRadiation
Undergo ISRT
Magnetic Resonance ImagingProcedure
Undergo MRI and/or PET-MRI
NivolumabBiological
Given IV
Positron Emission TomographyProcedure
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
PrednisoloneDrug
Given PO
PrednisoneDrug
Given PO
Procarbazine HydrochlorideDrug
Given PO
Questionnaire AdministrationOther
Ancillary studies
Vinblastine SulfateDrug
Given IV
Vincristine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) in rapid early responder (RER) patientsTime frame: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first
- PFS in slow-early responder (SER) patientsTime frame: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first
Locations
419 sites in 3 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama · Recruiting
USA Health Strada Patient Care Center
Mobile, Alabama · Recruiting
Providence Alaska Medical Center
Anchorage, Alaska · Recruiting
CTCA at Western Regional Medical Center
Goodyear, Arizona · Recruiting
Banner Children's at Desert
Mesa, Arizona · Recruiting
Cancer Center at Saint Joseph's
Phoenix, Arizona · Recruiting
Phoenix Childrens Hospital
Phoenix, Arizona · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Mercy Cancer Center - Carmichael
Carmichael, California · Recruiting
Mercy San Juan Medical Center
Carmichael, California · Recruiting
City of Hope Corona
Corona, California · Recruiting
UC Irvine Health Cancer Center-Newport
Costa Mesa, California · Recruiting
Kaiser Permanente Downey Medical Center
Downey, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Kaiser Permanente Dublin
Dublin, California · Recruiting
Mercy Cancer Center - Elk Grove
Elk Grove, California · Recruiting
Kaiser Permanente-Fremont
Fremont, California · Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California · Suspended
Kaiser Permanente-Fresno
Fresno, California · Recruiting
City of Hope Seacliff
Huntington Beach, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
City of Hope Antelope Valley
Lancaster, California · Recruiting
Loma Linda University Medical Center
Loma Linda, California · Recruiting
Miller Children's and Women's Hospital Long Beach
Long Beach, California · Recruiting
City of Hope at Long Beach Elm
Long Beach, California · Recruiting
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Valley Children's Hospital
Madera, California · Recruiting
Kaiser Permanente- Modesto MOB II
Modesto, California · Suspended
Kaiser Permanente-Modesto
Modesto, California · Recruiting
City of Hope Newport Beach
Newport Beach, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Children's Hospital of Orange County
Orange, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Mercy Cancer Center - Rocklin
Rocklin, California · Recruiting
Kaiser Permanente Downtown Commons
Sacramento, California · Recruiting
Mercy Cancer Center - Sacramento
Sacramento, California · Recruiting
Sutter Medical Center Sacramento
Sacramento, California · Recruiting
Kaiser Permanente-South Sacramento
Sacramento, California · Recruiting
Showing 40 of 419 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.